Does the media prefer BEAM or TWST?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 6 articles in the media. Twist Bioscience's average media sentiment score of 1.16 beat Beam Therapeutics' score of 0.62 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TWST or VCYT?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 11.58 -$77.67M -$1.33 N/A Veracyte $517.15M 7.29 $66.35M $1.09 43.37

Does the media refer more to TWST or VCYT?

In the previous week, Veracyte had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 21 mentions for Veracyte and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.16 beat Veracyte's score of 0.29 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer TWST or DNA?

In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.65 beat Twist Bioscience's score of 1.16 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, TWST or GMAB?

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 11.58 -$77.67M -$1.33 N/A Genmab A/S $3.72B 4.16 $963M $1.32 18.79

Does the media refer more to TWST or GMAB?

In the previous week, Twist Bioscience had 4 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Twist Bioscience and 2 mentions for Genmab A/S. Twist Bioscience's average media sentiment score of 1.16 beat Genmab A/S's score of 0.71 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or TWST?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Twist Bioscience. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.16 beat Ascendis Pharma A/S's score of 1.10 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$70.04 +0.82 (+1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$70.26 +0.22 (+0.32%)

As of 07:50 PM Eastern

Compare

TWST vs. BEAM, VCYT, DNA, GMAB, and ASND

Should you buy Twist Bioscience stock or one of its competitors? MarketBeat compares Twist Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Twist Bioscience include Beam Therapeutics (BEAM), Veracyte (VCYT), Ginkgo Bioworks (DNA), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.

How does Twist Bioscience compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Beam Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.92	-$79.99M	-$0.68	N/A
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A

In the previous week, Beam Therapeutics and Beam Therapeutics both had 6 articles in the media. Twist Bioscience's average media sentiment score of 1.16 beat Beam Therapeutics' score of 0.62 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Twist Bioscience has a net margin of -19.85% compared to Beam Therapeutics' net margin of -39.66%. Twist Bioscience's return on equity of -26.73% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Beam Therapeutics currently has a consensus target price of $46.83, indicating a potential upside of 57.26%. Twist Bioscience has a consensus target price of $58.00, indicating a potential downside of 17.19%. Given Beam Therapeutics' higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Beam Therapeutics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Veracyte?

Twist Bioscience (NASDAQ:TWST) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Twist Bioscience currently has a consensus price target of $58.00, suggesting a potential downside of 17.19%. Veracyte has a consensus price target of $47.57, suggesting a potential upside of 0.64%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Veracyte	16.25%	9.07%	8.38%

In the previous week, Veracyte had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 21 mentions for Veracyte and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.16 beat Veracyte's score of 0.29 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A
Veracyte	$517.15M	7.29	$66.35M	$1.09	43.37

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Twist Bioscience compare to Ginkgo Bioworks?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A
Ginkgo Bioworks	$170.15M	3.10	-$312.76M	-$5.36	N/A

Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Twist Bioscience presently has a consensus price target of $58.00, indicating a potential downside of 17.19%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential upside of 5.26%. Given Ginkgo Bioworks' higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.65 beat Twist Bioscience's score of 1.16 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Summary

Twist Bioscience beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Genmab A/S?

Twist Bioscience (NASDAQ:TWST) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

7.1% of Genmab A/S shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Twist Bioscience's net margin of -19.85%. Genmab A/S's return on equity of 15.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Genmab A/S	21.05%	15.34%	8.94%

Twist Bioscience presently has a consensus price target of $58.00, indicating a potential downside of 17.19%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 52.94%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A
Genmab A/S	$3.72B	4.16	$963M	$1.32	18.79

In the previous week, Twist Bioscience had 4 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Twist Bioscience and 2 mentions for Genmab A/S. Twist Bioscience's average media sentiment score of 1.16 beat Genmab A/S's score of 0.71 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Twist Bioscience. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.16 beat Ascendis Pharma A/S's score of 1.10 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S presently has a consensus target price of $295.39, suggesting a potential upside of 43.53%. Twist Bioscience has a consensus target price of $58.00, suggesting a potential downside of 17.19%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ascendis Pharma A/S has a net margin of 57.87% compared to Twist Bioscience's net margin of -19.85%. Ascendis Pharma A/S's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Twist Bioscience has lower revenue, but higher earnings than Ascendis Pharma A/S. Twist Bioscience is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	15.76	-$258M	$8.67	23.74
Twist Bioscience	$376.57M	11.58	-$77.67M	-$1.33	N/A

Summary

Ascendis Pharma A/S beats Twist Bioscience on 12 of the 15 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.31B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-52.66	10.38	20.24	21.95
Price / Sales	11.58	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	8.93	8.04	10.28	6.78
Net Income	-$77.67M	$23.89M	$3.57B	$337.51M
7 Day Performance	3.21%	-5.97%	-1.43%	-2.72%
1 Month Performance	23.20%	2.78%	3.27%	1.87%
1 Year Performance	121.86%	36.26%	23.37%	26.61%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.4372 of 5 stars	$70.04 +1.2%	$58.00 -17.2%	+119.3%	$4.31B	$376.57M	N/A	990	Positive News Gap Up
BEAM Beam Therapeutics	2.5285 of 5 stars	$31.14 -5.4%	$46.83 +50.4%	+58.2%	$3.39B	$139.74M	N/A	510	Gap Up
VCYT Veracyte	2.0081 of 5 stars	$48.18 +4.0%	$46.33 -3.8%	+77.5%	$3.70B	$541.74M	44.20	790
DNA Ginkgo Bioworks	1.9653 of 5 stars	$9.14 -2.5%	$8.50 -7.0%	+7.9%	$612.09M	$170.15M	N/A	640	Positive News Gap Up
GMAB Genmab A/S	4.2046 of 5 stars	$25.45 -3.3%	$37.93 +49.0%	+13.3%	$16.42B	$3.72B	19.28	3,029	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. BEAM, VCYT, DNA, GMAB, and ASND

How does Twist Bioscience compare to Beam Therapeutics?

Summary

How does Twist Bioscience compare to Veracyte?

Summary

How does Twist Bioscience compare to Ginkgo Bioworks?

Summary

How does Twist Bioscience compare to Genmab A/S?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. BEAM, VCYT, DNA, GMAB, and ASND

How does Twist Bioscience compare to Beam Therapeutics?

Do insiders & institutionals have more ownership in BEAM or TWST?

Which has better valuation & earnings, BEAM or TWST?

Does the media prefer BEAM or TWST?

Which has more risk & volatility, BEAM or TWST?

Is BEAM or TWST more profitable?

Do analysts rate BEAM or TWST?

Summary

How does Twist Bioscience compare to Veracyte?

Do analysts rate TWST or VCYT?

Which has more volatility and risk, TWST or VCYT?

Is TWST or VCYT more profitable?

Does the media refer more to TWST or VCYT?

Which has higher earnings and valuation, TWST or VCYT?

Summary

How does Twist Bioscience compare to Ginkgo Bioworks?

Which has stronger earnings and valuation, TWST or DNA?

Is TWST or DNA more profitable?

Do institutionals & insiders believe in TWST or DNA?

Do analysts recommend TWST or DNA?

Does the media prefer TWST or DNA?

Which has more volatility & risk, TWST or DNA?

Summary

How does Twist Bioscience compare to Genmab A/S?

Do insiders and institutionals believe in TWST or GMAB?

Is TWST or GMAB more profitable?

Do analysts recommend TWST or GMAB?

Which has more volatility & risk, TWST or GMAB?

Which has better valuation and earnings, TWST or GMAB?

Does the media refer more to TWST or GMAB?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Which has more risk & volatility, ASND or TWST?

Does the media favor ASND or TWST?

Do analysts rate ASND or TWST?

Is ASND or TWST more profitable?

Which has stronger valuation & earnings, ASND or TWST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools